GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Glycorex Transplantation AB (NGM:GTAB B) » Definitions » Net Cash per Share

Glycorex Transplantation AB (NGM:GTAB B) Net Cash per Share : kr-0.02 (As of Mar. 2025)


View and export this data going back to 1999. Start your Free Trial

What is Glycorex Transplantation AB Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Glycorex Transplantation AB's Net Cash per Share for the quarter that ended in Mar. 2025 was kr-0.02.

The historical rank and industry rank for Glycorex Transplantation AB's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of Glycorex Transplantation AB was 302.00. The lowest was 22.50. And the median was 32.61.

NGM:GTAB B's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 4.49
* Ranked among companies with meaningful Price-to-Net-Cash only.

Glycorex Transplantation AB Net Cash per Share Historical Data

The historical data trend for Glycorex Transplantation AB's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glycorex Transplantation AB Net Cash per Share Chart

Glycorex Transplantation AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.32 0.16 -0.11 -0.14

Glycorex Transplantation AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.17 -0.15 -0.14 -0.02

Competitive Comparison of Glycorex Transplantation AB's Net Cash per Share

For the Biotechnology subindustry, Glycorex Transplantation AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glycorex Transplantation AB's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Glycorex Transplantation AB's Price-to-Net-Cash falls into.


;
;

Glycorex Transplantation AB Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Glycorex Transplantation AB's Net Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as

Net Cash per Share (A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(6.753-17.19-0)/73.854
=-0.14

Glycorex Transplantation AB's Net Cash per Share for the quarter that ended in Mar. 2025 is calculated as

Net Cash per Share (Q: Mar. 2025 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(14.477-15.72-0)/82.122
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glycorex Transplantation AB  (NGM:GTAB B) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Glycorex Transplantation AB Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Glycorex Transplantation AB's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Glycorex Transplantation AB Business Description

Traded in Other Exchanges
Address
Solvegatan 41, Lund, SWE, 223 70
Glycorex Transplantation AB is a biotechnology company. The company is involved in the development, production, and sales of organ transplantation. Its product includes Glycosorb-ABO which facilitates the transplantation of organs over the blood group barriers. The group has more than 130 transplant centers in approximately 23 countries.

Glycorex Transplantation AB Headlines

No Headlines